Preliminary Results Demonstrate That the Novel Delivery of Dexamethasone via Mercator MedSystems, Inc.’s Platform Micro-Infusion Catheter Inhibits Restenosis for at Least 9 Months in 10 Patients Treated for Peripheral Vascular Disease (PAD)

SAN LEANDRO, Calif.--(BUSINESS WIRE)--Mercator MedSystems, a medical technology company whose platform Micro-Infusion Catheter technology—catheter-guided, microfluid injection systems for site-specific, non-systemic delivery of therapeutic agents directly across any peripheral or coronary blood vessel to treat peripheral vascular diseases, cancer, heart attacks, and other life-threatening diseases and disorders—announced today preliminary results of its ‘DANCE’ clinical trial that continues to follow patients at the University of California, San Francisco (UCSF) and San Francisco VA Medical Center.